(NU/1433-27) iFAST: The Provision of Business Consultancy to Assist Commercialisation of University Research

Concepts

• management consultancy
• provision of business consultancy
• assist commercialisation of university research
• newcastle
• consultancy services
• combined burden of influenza
• antimicrobial resistance
• impact of amr
• ceo desig
• breakthrough technology

Location

Description

The emergence of bacteria that are resistant to antibiotics is a growing public health problem. In 2015, there were nearly 700,0000 antimicrobial resistance (AMR) infections in the EU, accounting for 33,000 deaths and 900,000 disability-adjusted life years (DALYs) . In fact the impact of AMR is similar to the combined burden of influenza, tuberculosis, and HIV, and the global increases in healthcare costs is forecast to range from $300 billion to more than $1 trillion per year by 2050. We have developed a breakthrough technology that delivers an antibiotic resistance test result in 1 hour. The technique rapidly measures phenotypic changes in bacteria after exposure to antibiotics. The objective is for the Executive (CEO Desig) to jointly work in a team with all above named individuals to bring the opportunity towards and ultimately achieve launch of a new spinout company.

Award Detail

CPV Codes

• 79400000 - Business and management consultancy and related services

Indicators

• Contract is suitable for SMEs.